Treatment of Continuous Cough in Asthma Patients with Common Cold
For an asthma patient with continuous cough during a common cold, initiate or optimize inhaled corticosteroids (ICS) as first-line therapy, with consideration of adding a leukotriene receptor antagonist if response is incomplete. 1
Primary Treatment Approach
The 2020 CHEST guidelines provide clear direction: inhaled corticosteroids are the cornerstone of treatment for cough in asthma patients (Grade 1B recommendation). 1 This applies whether the patient has typical asthma or cough variant asthma (CVA), and the evidence base supporting stepwise ICS treatment is very strong.
Initial Management Algorithm:
Step 1: Start or optimize ICS therapy
- If not already on ICS: Begin low-to-medium dose ICS immediately
- If already on ICS: Consider stepping up the dose
- Beta-agonists can be added in combination with ICS for symptom relief 1
Step 2: If incomplete response after reassessment
- Increase ICS dose further
- Add a leukotriene receptor antagonist (e.g., montelukast)
- Reconsider alternative causes of cough 1
Why This Approach Works
Common colds trigger asthma exacerbations through viral-induced airway inflammation, bronchial hyperresponsiveness, and increased asthma symptoms. 2 Research demonstrates that budesonide/formoterol maintenance and reliever therapy reduced severe cold-related exacerbations by 36-52% compared to other regimens, with the ICS component being critical for reducing cold-related exacerbations. 3
The cough mechanism in asthma involves eosinophilic airway inflammation and bronchoconstriction, both of which respond to corticosteroids. 1, 4 Approximately 30-40% of CVA patients may progress to classic asthma if inadequately treated, making early aggressive ICS therapy essential. 4
Important Clinical Considerations
Common Pitfall to Avoid: Do not rely solely on short-acting beta-agonists (SABA) for symptom relief. While they provide temporary relief, they do not address the underlying inflammatory process that drives cough during viral infections. 3
Biomarker Guidance: If available, elevated eosinophils (blood ≥150/μl) or fractional exhaled nitric oxide (FeNO ≥35 ppb) predict better corticosteroid response and support more aggressive anti-inflammatory therapy. 1, 5
Duration of Treatment: ICS therapy should continue for at least 8 weeks for CVA, and longer for typical asthma. 5 Do not discontinue prematurely even if symptoms improve, as this increases risk of progression to classic asthma.
Symptomatic Adjuncts
While the primary focus is anti-inflammatory therapy, antihistamine-decongestant combinations can reduce cough severity by 20-30% within the first few days by addressing upper respiratory symptoms like postnasal drip that contribute to cough. 6 However, this is adjunctive to—not a replacement for—ICS therapy in asthma patients.
When to Escalate
If cough persists despite optimized ICS-LABA therapy at medium-to-high doses:
- Consider adding leukotriene receptor antagonist 1
- Reassess for comorbidities (rhinosinusitis, GERD, bronchiectasis) 7
- Evaluate for severe asthma requiring biologic therapy 5
- Refer to asthma specialist if uncontrolled on Step 4 treatment 5
Critical Safety Note: Long-term high-dose ICS (above recommended clinical ranges) may cause systemic adverse effects including osteoporosis and HPA axis suppression. Use the lowest effective dose that maintains control. 5